Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Adlai Nortye

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Sep 29, 2022 11:33am

133 Views

Post# 34994953

RE:RE:RE:RE:RE:Adlai Nortye

Should read .. " In March 2022 Adlai Nortye reported that it had advanced to the third and final dose escalation cohort of the bridging clinical trial evaluating the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced or metastatic breast cancer.

Adlai Nortye's pelareorep + paclitaxel dose escalation study were in Chinese patients to demonstrate safety, tolerability and preliminary effectiveness in Asian patient populations as opposed to ONCY's IND-213 and Bracelet-1 Phase 2 clinical trial, which were primarily conducted on European derived AND African-American patients."

<< Previous

Bullboard Posts

Next >>

ArcStone-Kingswood Growth Summit 2024: A premier growth conference